OncLive TV

Marisol Miranda-Galvis, DDS, MS, PhD, discusses the investigation of disparities in survival outcomes of patients with hematologic malignancies relating to social determinants.

Anthony M Hunter, MD, discusses the current treatment landscape with JAK inhibitors in myelofibrosis.

Luciano J. Costa, MD, PhD, discusses clinical implications derived from a final analysis of the phase 2 MASTER trial, which evaluated quadruplet induction therapy in multiple myeloma.

Joshi Alumkal, MD, discusses treatment options for patients with metastatic castrate-resistant prostate cancer harboring homologous recombination deficient alterations, including PARP inhibitors.

David Harpole, MD, discusses findings from an exploratory analysis of the phase 3 AEGEAN trial in patients with EGFR-mutated non–small cell lung cancer.

Pasi A. Jänne, MD, PhD, discusses findings from the phase 3 FLAURA2 trial in patients with EGFR-mutant non–small cell lung cancer.

Guillermo Garcia-Manero, MD, discusses the key efficacy findings from the phase 3 COMMANDS trial evaluating luspatercept-aamt in patients with myelodysplastic syndrome who were erythropoiesis-stimulating agent naïve and red blood cell transfusion dependent.

Harry Erba, MD, PhD, discusses the role of quizartinib for the treatment of newly diagnosed patients with FLT3-ITD–positive acute myeloid leukemia.

Monica D. Mead, MD, discusses the importance of addressing unanswered questions in the treatment of patients with mantle cell lymphoma.

Loretta J. Nastoupil, MD, discusses the safety and efficacy data from the phase 2 TRANSCEND FL trial evaluating lisocabtagene maraleucel in patients with relapsed/refractory follicular lymphoma.

Brad S. Kahl, MD, discusses the potential for BTK inhibitors to shift the frontline treatment setting in mantle cell lymphoma.

Jules Lin, MD, discusses how approaches to surgical intervention in non–small cell lung cancer may have shifted with the increasing use of targeted therapy and immunotherapies in the adjuvant and neoadjuvant setting.

Daneng Li, MD, discusses the investigation of triplet combination therapy for patients with hepatocellular carcinoma in the phase 1/2 Morpheus-Liver study.

Erika P. Hamilton, MD, discusses the benefit seen with adjuvant ribociclib in patients with hormone receptor-positive,HER2-negative breast cancer.

Abhinav Deol, MD, discusses ongoing and potential research avenues for improving the use of CAR T-cell therapy in multiple myeloma.

Michael J. Birrer, MD, PhD, discusses the benefits of molecular profiling in patients with endometrial cancer, the variety of mutations that have been identified in this disease, and how stratifying patients based on the biomarkers their disease harbors allows for more individualized treatment decisions.

Nathaniel Myall, MD, clinical assistant professor, medicine - oncology, Stanford Medicine, discusses efficacy findings from 3 clinical trials investigating combination immunotherapy and chemoimmunotherapy treatment approaches in patients with non–small cell lung cancer.

Abhinav Deol, MD, discusses the sequencing of CAR T-cell therapies with other readily available agents in multiple myeloma.

Afsaneh Barzi, MD, PhD, discusses unmet needs associated with the adjuvant treatment of patients with gastroesophageal cancers and highlights the use of nivolumab in this setting.

Bhavana Pothuri, MD, discusses the promise of the phase 3 NRG-GY018 and RUBY trials in patients with endometrial cancer.

Yi Lin, MD, PhD, discusses the patient characteristic for those with relapsed/refractory multiple myeloma who experienced sustained minimal residual disease negativity following treatment with ciltacabtagene autoleucel during the phase 1/2 CARTITUDE-1 trial.

Yi Lin, MD, PhD, the predictive value of baseline characteristics in relation to sustained minimal residual disease negativity following treatment with ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

Bryan Schneider, MD, discusses agents available for use in the targeting of MET exon 14 mutations in non–small cell lung cancer.

Hagop M. Kantarjian, MD, discusses the predictive value of early landmark cytogenetic or molecular responses to ponatinib in heavily pretreated patients with chronic-phase chronic myeloid leukemia.

Mazyar Shadman, MD, MPH, discusses the efficacy and safety of zanubrutinib in chronic lymphocytic leukemia, as well as data derived from the agents use which supports the regulatory approval of zanubrutinib in this patient population.

Martin Cannon, PhD, discusses data seen with immune checkpoint inhibitors in patients with ovarian cancer and why these agents are not as effective in this population as they are in other cancer types.

John Burke, MD, discusses the evolution of the diffuse large B-cell lymphoma treatment paradigm.

Lyudmila A. Bazhenova, MD, discusses how to treat patients with non–small cell lung cancer who present with EGFR mutations, highlights how to accurately pinpoint gaps in lung cancer care, and expands on how to address these gaps in patients with non–small cell lung cancer.

Kathleen N. Moore, MD, MS, discusses the design of the ongoing, first-in-human, phase 1/2 study of the MUC16- and CD3-targeted bispecific antibody ubamatamab alone or in combination with cemiplimab in patients with recurrent ovarian cancer.

Daneng Li, MD, discusses how immune-related adverse effects can affect the treatment of patients with gastrointestinal cancer, specifically those with unresectable hepatocellular carcinoma.